
Sept. 23 - In this edition of Equity Forum, S&P Equity analyst Jeffrey Englander notes that Edwards Lifesciences Corp. (EW)
develops, manufactures and markets products and technologies that are designed to treat advanced stage cardiovascular disease. He currently has a "5-Star" Strong Buy recommendation for Edwards Lifesciences Corp (EW).